Palliative care research: Lessons learned by our team over the last 25 years

Abstract

Background:

In the last 25 years, palliative care has made major progress as an interdisciplinary specialty that addresses quality-of-life issues for patients with life-limiting illnesses and their families. Research by numerous investigators has contributed to our increasing body of knowledge to support an evidence-based practice.

Aim:

We highlight some lessons learned by our group in the process of conducting palliative care research, focusing in particular on symptom assessment; the management of pain, fatigue, cachexia, dyspnea, delirium, and opioid-induced neurotoxicity; and outcomes of our palliative care program.

Design:

Narrative review of selected literature, focusing on studies conducted by our group.

Data sources:

This article is based on the Second Vittorio Ventafridda Memorial Lecture by Dr Eduardo Bruera, delivered at the European Association for Palliative Care, Trondheim, Norway on 8 June 2012.

Results:

For each topic, we review some of the pivotal studies in palliative care, discuss the challenges in research design, and outline possible directions for future research.

Conclusions:

We conclude by sharing some of what we learned about the processes, pearls, and pitfalls of palliative care research.

Keywords

Cachexia delirium dyspnea fatigue health services neoplasms opioid analgesics pain palliative care patient outcome assessment research

Get full access to this article

View all access options for this article.

References

World Health Organization. WHO definition of palliative care, http://www.who.int/cancer/palliative/definition/en/(2002, accessed 1 March 2011).

Saunders

. What’s in a name? Palliat Med 1987; 1: 57–61.

Saunders

Introduction: history and challenge. In: Saunders

Sykes

(eds). The management of terminal malignant disease. 3rd ed. London: Hodder & Stoughton, 1993, pp. 1–14.

Hui

Reddy

Parsons

. Reporting of funding sources and conflict of interest in the supportive and palliative oncology literature. J Pain Symptom Manage 2012; 44: 421–430.

Hui

Parsons

Damani

. Quantity, design, and scope of the palliative oncology literature. Oncologist 2011; 16: 694–703.

Hui

Elsayem

De la Cruz

. Availability and integration of palliative care at US cancer centers. JAMA 2010; 303: 1054–1061.

Dorman

Byrne

Edwards

. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review. Palliat Med 2007; 21: 177–191.

Hjermstad

Gibbins

Haugen

. Pain assessment tools in palliative care: an urgent need for consensus. Palliat Med 2008; 22: 895–903.

Holen

Hjermstad

Loge

. Pain assessment tools: is the content appropriate for use in palliative care? J Pain Symptom Manage 2006; 32: 567–580.

10.

Vodermaier

Linden

Siu

. Screening for emotional distress in cancer patients: a systematic review of assessment instruments. J Natl Cancer Inst 2009; 101: 1464–1488.

11.

Yennurajalingam

Bruera

. Palliative management of fatigue at the close of life: “it feels like my body is just worn out.” JAMA 2007; 297: 295–304.

12.

Snaith

. The hospital anxiety and depression scale. Health Qual Life Outcomes 2003; 1: 29.

13.

Bruera

Kuehn

Miller

. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7: 6–9.

14.

Chang

Hwang

Feuerman

. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000; 88: 2164–2171.

15.

Carvajal

Centeno

Watson

. A comprehensive study of psychometric properties of the Edmonton Symptom Assessment System (ESAS) in Spanish advanced cancer patients. Eur J Cancer 2011; 47: 1863–1872.

16.

Cummings

Biondo

Campbell

. Can the global uptake of palliative care innovations be improved? Insights from a bibliometric analysis of the Edmonton Symptom Assessment System. Palliat Med 2011; 25: 71–82.

17.

Dudgeon

King

Howell

. Cancer Care Ontario’s experience with implementation of routine physical and psychological symptom distress screening. Psychooncology 2012; 21: 357–364.

18.

Kaasa

Wessel

. The Edmonton Functional Assessment Tool: further development and validation for use in palliative care. J Palliat Care 2001; 17: 5–11.

19.

Bruera

MacMillan

Hanson

. The Edmonton staging system for cancer pain: preliminary report. Pain 1989; 37: 203–209.

20.

Cantwell

Turco

Brenneis

. Predictors of home death in palliative care cancer patients. J Palliat Care 2000; 16: 23–28.

21.

Ventafridda

Saita

Ripamonti

. WHO guidelines for the use of analgesics in cancer pain. Int J Tissue React 1985; 7: 93–96.

22.

Ventafridda

Tamburini

Caraceni

. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59: 850–856.

23.

Walsh

MacDonald

Bruera

. A controlled study of sustained-release morphine sulfate tablets in chronic pain from advanced cancer. Am J Clin Oncol 1992; 15: 268–272.

24.

Bruera

Sloan

Mount

. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. J Clin Oncol 1996; 14: 1713–1717.

25.

Bruera

Belzile

Pituskin

. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998; 16: 3222–3229.

26.

Ling

Mooney

Hillhouse

. Prescription opioid abuse, pain and addiction: clinical issues and implications. Drug Alcohol Rev 2011; 30: 300–305.

27.

Administration USDE. Fact sheet: prescription drug abuse. Springfield 2012, http://www.justice.gov/dea/index.html (accessed 3 February 2013).

28.

Bruera

De Lima

. Opioid cost: a global problem. Palliat Med 2005; 19: 504.

29.

Rose

Krzyzanowska

Joffe

. Relationships between authorship contributions and authors’ industry financial ties among oncology clinical trials. J Clin Oncol 2010; 28: 1316–1321.

30.

Lathyris

Patsopoulos

Salanti

. Industry sponsorship and selection of comparators in randomized clinical trials. Eur J Clin Invest 2010; 40: 172–182.

31.

Als-Nielsen

Chen

Gluud

. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003; 290: 921–928.

32.

Bekelman

Gross

. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289: 454–465.

33.

Hui

Arthur

Dalal

. Quality of the supportive and palliative oncology literature: a focused analysis on randomized controlled trials. Support Care Cancer 2012; 20: 1779–1785.

34.

Hui

Bruera

. Breakthrough pain in cancer patients: the need for evidence. Eur J Palliat Care 2010; 17: 58–67.

35.

Bruera

Chadwick

Brenneis

. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71: 67–70.

36.

Bruera

Fainsinger

MacEachern

. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992; 50: 75–77.

37.

Bruera

Miller

Macmillan

. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992; 48: 163–166.

38.

Bruera

Driver

Barnes

. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report. J Clin Oncol 2003; 21: 4439–4443.

39.

Bruera

Valero

Driver

. Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial. J Clin Oncol 2006; 24: 2073–2078.

40.

Cruz

Hui

Parsons

. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer 2010; 116: 766–774.

41.

Bruera

Yennurajalingam

Perez-Cruz

. Methylphenidate (MP) and nursing telephone intervention (NTI) for cancer-related fatigue (CRF) in advanced cancer patients: a double-blind randomized phase II trial. J Clin Oncol 2012; 30(suppl): abstract 9023.

42.

Moertel

Schutt

Reitemeier

. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33: 1607–1609.

43.

Bruera

Roca

Cedaro

. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69: 751–754.

44.

Yennurajalingam

Frisbee-Hume

Delgado-Guay

. Dexamethasone (DM) for cancer related fatigue: a double-blinded, randomized, placebo-controlled trial. J Clin Oncol 2012(suppl); 30: abstract 9002.

45.

Mulhern

Khan

Kaplan

. Short-term efficacy of methylphenidate: a randomized, double-blind, placebo-controlled trial among survivors of childhood cancer. J Clin Oncol 2004; 22: 4795–4803.

46.

Thompson

Leigh

Christensen

. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001; 19: 1802–1808.

47.

Bruera

Ernst

Hagen

. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998; 2: 74–78.

48.

Bruera

Macmillan

Kuehn

. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990; 66: 1279–1282.

49.

Strang

. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res 1997; 17: 657–662.

50.

Prevost

Grach

. Nutritional support and quality of life in cancer patients undergoing palliative care. Eur J Cancer Care (Engl) 2012; 21: 581–590.

51.

Bruera

Belzile

Neumann

. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 2000; 19: 427–435.

52.

Bruera

Moyano

Sala

. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage 2004; 28: 381–388.

53.

Bruera

Strasser

Palmer

. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003; 21: 129–134.

54.

Del Fabbro

Hui

Dalal

. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med 2011; 14: 1004–1008.

55.

Bruera

De Stoutz

Velasco-Leiva

. Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 1993; 342: 13–14.

56.

Bruera

Sweeney

Willey

. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 2003; 17: 659–663.

57.

Bruera

MacEachern

Ripamonti

. Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 1993; 119: 906–907.

58.

Bruera

Sala

Spruyt

. Nebulized versus subcutaneous morphine for patients with cancer dyspnea: a preliminary study. J Pain Symptom Manage 2005; 29: 613–618.

59.

Hui

Morgado

Chisholm

. High flow oxygen and bilevel positive airway pressure for persistent dyspnea in patients with advanced cancer: a phase II randomized trial. J Pain Symptom Manage 2013; (in press).

60.

Reddy

Parsons

Elsayem

. Characteristics and correlates of dyspnea in patients with advanced cancer. J Palliat Med 2009; 12: 29–36.

61.

Bruera

Miller

McCallion

. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage 1992; 7: 192–195.

62.

Bruera

Spachynski

MacEachern

. Cognitive failure in cancer patients in clinical trials. Lancet 1993; 341: 247–248.

63.

Hui

Kilgore

Fellman

. Development and cross-validation of the in-hospital mortality prediction in advanced cancer patients (IMPACT) score: a preliminary study. J Palliat Med 2012; 15: 902–909.

64.

Lawlor

Gagnon

Mancini

. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000; 160: 786–794.

65.

Bruera

Bush

Willey

. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer 2009; 115: 2004–2012.

66.

Hui

Bush

Gallo

. Neuroleptic dose in the management of delirium in patients with advanced cancer. J Pain Symptom Manage 2010; 39: 186–196.

67.

Hui

Reddy

Palla

. Neuroleptic prescription pattern for delirium in patients with advanced cancer. J Palliat Care 2011; 27: 141–147.

68.

Bruera

Sweeney

Willey

. Perception of discomfort by relatives and nurses in unresponsive terminally ill patients with cancer: a prospective study. J Pain Symptom Manage 2003; 26: 818–826.

69.

Daeninck

Bruera

. Opioid use in cancer pain. Is a more liberal approach enhancing toxicity? Acta Anaesthesiol Scand 1999; 43: 924–938.

70.

Bush

Bruera

. The assessment and management of delirium in cancer patients. Oncologist 2009; 14: 1039–1049.

71.

De Stoutz

Bruera

Suarez-Almazor

. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378–384.

72.

Mercadante

Bruera

. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006; 32: 304–315.

73.

Lawlor

Turner

Hanson

. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 1998; 82: 1167–1173.

74.

Bruera

Sweeney

. Methadone use in cancer patients with pain: a review. J Palliat Med 2002; 5: 127–138.

75.

Walker

Palla

Pei

. Switching from methadone to a different opioid: what is the equianalgesic dose ratio? J Palliat Med 2008; 11: 1103–1108.

76.

Reddy

Hui

El Osta

. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med 2010; 13: 33–38.

77.

Parsons

De la Cruz

El Osta

. Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 2010; 116: 520–528.

78.

Bruera

Neumann

Gagnon

. Edmonton Regional Palliative Care Program: impact on patterns of terminal cancer care. CMAJ 1999; 161: 290–293.

79.

Elsayem

Swint

Fisch

. Palliative care inpatient service in a comprehensive cancer center: clinical and financial outcomes. J Clin Oncol 2004; 22: 2008–2014.

80.

Osta

Palmer

Paraskevopoulos

. Interval between first palliative care consult and death in patients diagnosed with advanced cancer at a comprehensive cancer center. J Palliat Med 2008; 11: 51–57.

81.

Fadul

Elsayem

Palmer

. Supportive versus palliative care: what’s in a name? A survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer 2009; 115: 2013–2021.

82.

Dalal

Palla

Hui

. Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center. Oncologist 2011; 16: 105–111.

83.

Dev

Miles

Del Fabbro

. Growth of an academic palliative medicine program at a comprehensive cancer center. J Pain Symptom Manage 2013; 45: 261–271.

84.

Bruera

Franco

Maltoni

. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995; 10: 287–291.

85.

Montedori

Bonacini

Casazza

. Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study. Trials 2011; 12: 58.